Can the Relative Fecal Abundance of BLSE and the Digestive Microbiota be Predictive of the Risk of Infection in a Carrier Patient? (COPROBLSE2)
Enterobacteria Infections
About this trial
This is an interventional diagnostic trial for Enterobacteria Infections
Eligibility Criteria
Inclusion Criteria:
- Adult patient (≥ 18 years old) hospitalized at the Paris Saint-Joseph Hospital Group or in the intensive care unit of Avicenne hospital, Necker Enfants Malades hospital, Center Sud Francilien, detected as a carrier of enterobacteriaceae in the digestive system ESBL producers
- Patient affiliated to a health insurance plan
- French-speaking patient
- Patient living at home, in EHPAD or retirement home
- Patient or Relative able to give free, informed and express consent
Exclusion Criteria:
- Known patient colonized rectally with ESBL-producing enterobacteria and subjected to antibiotic pressure other than beta-lactams
- Patient participating simultaneously in other intervention research that may interfere with the objectives of the study
- Patient under guardianship or curatorship
- Patient deprived of liberty
- Pregnant or breastfeeding woman
Sites / Locations
- Groupe Hospitalier Paris Saint-JosephRecruiting
- Hôpital Necker-Enfants malades
- Hôpital Avicenne
- Centre Hospitalier Sud-Francilien
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Control: Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure
Case: Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure
Known patients colonized rectally with ESBL-producing enterobacteria and not subjected to antibiotic pressure
Known patients colonized rectally with ESBL-producing enterobacteriaceae and subjected to antibiotic pressure (antibiotic therapy predicted greater than 24 hours) with beta-lactams or dual therapy comprising a beta-lactam. The prescription of antibiotic therapy, a decision independent of the study procedures, will be carried out as part of routine care in the context of microbiologically documented infection. The choice of molecules will be left to the discretion of clinicians.